Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

d that the Genous Stent, which accelerates the natural healing process, enables a shorter post-procedural period of DAPT without increasing the risk of late or very late stent thrombosis and without causing dangerous delays for patients who require non-cardiac surgery shortly after PCI."

The single-center study investigated 61 high-risk patients with a clear contraindication to prolonged DAPT. A high-risk condition was defined as meeting at least two of the following criteria: diabetes, acute coronary syndrome, heart failure, proximal vessel disease, multivessel disease, B2/C type lesions, bifurcating lesions and long lesions.  The study's primary outcome measures were the occurrences of death, MI, target vessel revascularization (TVR), target lesion revascularization (TLR) and MACE, defined as a non-hierarchical composite of all cause death, nonfatal MI or repeat revascularization.

"This study adds to the growing body of knowledge published in peer-reviewed biomedical publications that supports the use of Genous for the treatment of challenging coronary indications," said Stephen M. Rowland, Ph.D., vice president of research and development at OrbusNeich. "We see in this case that high-risk patients with confounding co-morbidities precluding the use of DES still have an option that is safe and effective in the long-term."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting ste
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... of pharmaceutical marketing and, consequently, organizations are turning ... for patients. As part of this ... it,s important to educate, communicate and engage patients ... disease awareness to patient empowerment. By mapping the ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... 2011 A letter sent by a commercial insurer ... drug use when combining anti-clotting drug clopidogrel (Plavix®) with ... in the number of members combining the drugs, according ... leader Prime Therapeutics (Prime). Details of the study will ...
... PHOENIX, April 18, 2011 Altitude Organic Corporation ... company, announced today that it has launched its ... Scottsdale headquarters.  Visit the DoctorMMJ.com website ( www.DoctorMMJ.com ... professional, and entirely legal medical marijuana evaluation in ...
Cached Medicine Technology:Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 3
(Date:7/13/2014)... MyDressCity.com, one of the most popular suppliers of wedding ... new range of elegant Quinceanera dresses . What’s ... prices. Worldwide clients can enjoy this special offer before ... shop, there are plenty of beautiful dresses for sale, ... MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, wedding ...
(Date:7/13/2014)... July 13, 2014 Epidemiologists forecast an ... the 6MM, from 8,062 diagnosed incident cases in 2013 ... Annual Growth Rate (AGR) of 4.35%, during the forecast ... number of diagnosed incident cases of aGVHD in the ... have the lowest number of diagnosed incident cases of ...
(Date:7/13/2014)... ability to identify odors might indicate the development ... of the eye could indicate the build-up of ... brain, according to the results of four research ... Conference 2014 (AAIC 2014) in Copenhagen. , In ... identify odors was significantly associated with loss of ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... Hills, California (PRWEB) July 13, 2014 ... Danny Musico has formed a promotional partnership with Aqua ... plant based Omega-3 EPA supplement . The collaboration ... is a celebrity fitness trainer , actor, model, ... Hollywood’s go-to trainer for A-List celebrities, he has prepared ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... Henry Ford Hospital is hosting a wine,tasting event to raise ... 16 at the Detroit Yacht Club. The event is ... of Eastern Market. The evening will include light dinner ... helps support functions for stroke education and the annual,Stroke Retreat ...
... Boston, BOSTON, Nov. 5 Insight Forums, ... as the winner of the 2007 Insight Award,for ... ceremony at,the Healthcare Communications Forum in Boston, the ... of,health care services need to make fully informed ...
... Tuesday, November 6, 2007, SAN DIEGO, Nov. 5 ... that Neurocrine Biosciences will,present at the CIBC World Markets ... Tuesday, November 6, 2007 at 8:00 a.m.,Eastern Time (ET)/5:00 ... and may be accessed on the Company,s website at, ...
... Inc. (Amex: CTE ), a developer and ... treatment of cardiovascular and other,diseases, announced today that ... results before the market opens on Tuesday, November ... a conference call for,investors at 2:30 p.m. ET ...
... 5 The following is a,statement by Bonnie J. ... Milwaukee jury unanimously concluded that former manufacturers,of lead pigment ... for the,harm claimed by this plaintiff. The jury unanimously ... in paint., "Under Wisconsin law, property owners are ...
... COLUMBIA, Md., Nov. 5 Already a leader ... Biosciences Corporation,announced today that it will be expanding ... worldwide exclusive distributorship agreement for its DHA,Gold(R) product ... Novus,s,exclusive worldwide DHA supplier for all of its ...
Cached Medicine News:Health News:Aetna HSA Online Video Wins 2007 Insight Award for Customer Advocacy in Healthcare 2Health News:CardioTech Announces Conference Call on November 13 at 2:30 PM Eastern For Second Quarter of Fiscal 2008 2Health News:Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International 2Health News:Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: